Premium
Pioglitazone may impair L‐DOPA anti‐parkinsonian efficacy in the MPTP ‐lesioned macaque: Results of a pilot study
Author(s) -
Huot Philippe,
Johnston Tom H.,
Fox Susan H.,
Brotchie Jonathan M.
Publication year - 2015
Publication title -
synapse
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 106
eISSN - 1098-2396
pISSN - 0887-4476
DOI - 10.1002/syn.21801
Subject(s) - pioglitazone , mptp , parkinson's disease , pharmacology , dyskinesia , medicine , agonist , macaque , receptor , endocrinology , diabetes mellitus , type 2 diabetes , disease , psychology , neuroscience
In this pilot study, pioglitazone, an agonist of the peroxisome proliferator‐activated receptor gamma (PPAR‐γ) used in the treatment of diabetes mellitus, was administered to dyskinetic parkinsonian macaques. Pioglitazone alleviated L‐DOPA‐induced dyskinesia, but impaired L‐DOPA anti‐parkinsonian efficacy. These results suggest caution when administering pioglitazone to patients with advanced Parkinson's disease.